Page 95 - GHES-1-1

Global Health Econ Sustain Impact of new drug indications in Brazil

expanded indications. Such an assessment could provide Project administration: Silvana Marcia Bruschi Kelles
valuable insights into the value of these treatments in Supervision: Ernesto Gomes de Azevedo, Sergio Adriano
different patient populations, informing decision-making Loureiro Bersan, Silvana Marcia Bruschi Kelles
processes and resource allocation strategies. Visualization: Daniel Pitchon dos Reis, Geraldo José
The economic impact of expanded indications for Coelho Ribeiro, Júlia Teixeira Tupinambás, Karina
drugs, particularly in oncology and rare diseases, will de Castro Zocrato, Lélia Maria de Almeida Carvalho,
depend on several factors, including the size of the eligible Marcela Pinto de Freitas, Maria da Glória Cruvinel
patient population for treatment with the drug, the cost Horta
of the drug itself, and the potential benefits of treatment Writing – original draft: Marcus Carvalho Borin, Mariana
in terms of improved patient outcomes and reduced Michel Barbosa, Silvana Marcia Bruschi Kelles
healthcare costs. Writing – review & editing: Marcus Carvalho Borin,
Mariana Michel Barbosa, Silvana Marcia Bruschi
5. Conclusion Kelles
Pharmaceutics has brought clinical benefits in many Ethics approval and consent to participate
areas. However, the costs of these benefits are becoming
unsustainable for many countries and health systems. Not applicable.
Expanding the range of uses for drugs such as trastuzumab
deruxtecan and pembrolizumab can have a significant Consent for publication
impact on healthcare budgets and jeopardize the Not applicable.
sustainability of health-care systems. In Brazil, where drug
prices are not closely monitored after initial registration, Availability of data
the only changes in prices occur due to the annual inflation- Data can be obtained from the corresponding author
regulated adjustment. Monitoring drug prices after their following a formal request.
initial pricing is crucial to assess the need for adjustments,
particularly when new therapeutic options for the same References
condition become available or when a drug becomes
obsolete. It is essential to revise and adjust drug prices after Bach, P.B., & Saltz, L.B. (2017). Raising the dose and raising
their initial pricing to ensure that health systems remain the cost: The case of Pembrolizumab in lung cancer. JNCI:
Journal of the National Cancer Institute, 109:djx125.
sustainable and can provide the best possible treatment
for patients. Policymakers must be aware of this unique https://doi.org/10.1093/jnci/djx125
challenge. Brewer, G.J. (2006). Article commentary: Fundamental problems
lie ahead in the drug discovery and commercialization
Acknowledgments process: Restructuring of the pharmaceutical industry
None. and an improved partnership with academia are required.
Journal of Investigative Medicine, 54(6):291-302.
Funding https://doi.org/10.2310/6650.2006.05030
This study was fully supported by Unimed-BH. CMED. (2004). Resolução CMED No 2, De 5 De Março De
2004-Português (Brasil). Available from: https://www.
Conflict of interest gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/
The authors declare that they have no competing interests. air/arquivos/5517json-file-1/view [Last accessed on
2023 Jan 20].
Author contributions Columbia University Mailman School of Public Health. (2020).
Conceptualization: Marcus Carvalho Borin, Mariana Brazil Summary. Columbia University Mailman School of
Michel Barbosa, Camila Oliveira Pereira, Silvana Public Health. Available from: https://www.publichealth.
Marcia Bruschi Kelles. columbia.edu/research/others/comparative-health-policy-
Investigation: Marcus Carvalho Borin, Mariana Michel library/brazil-summary [Last accessed on 2023 Nov 07].
Barbosa, Camila Oliveira Pereira, Silvana Marcia Cruz, J.A.W., da Cunha, M.A.V.C., de Moraes, T.P., Marques, S.,
Bruschi Kelles Tuon, F.F., Gomide, A.L., et al. (2022). Brazilian private
Methodology: Marcus Carvalho Borin, Mariana Michel health system: History, scenarios, and trends. BMC Health
Barbosa, Carina Rejane Martins, Mariza Cristina Services Research, 22:49.
Torres Talim https://doi.org/10.1186/s12913-021-07376-2

Volume 1 Issue 1 (2023) 8 https://doi.org/10.36922/ghes.0994